SRT2104

SRT-2104

SRT-2104

Organic compound, experimental pharmaceuticum


SRT-2104 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. The compound progressed to Phase II human trials for Type II diabetes before development was discontinued, however it continues to be widely used in animal research into the functions of SIRT1.[1][2][3][4][5]

Quick Facts Identifiers, CAS Number ...

See also


References

  1. Baksi A, Kraydashenko O, Zalevkaya A, Stets R, Elliott P, Haddad J, et al. (July 2014). "A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes". British Journal of Clinical Pharmacology. 78 (1): 69–77. doi:10.1111/bcp.12327. PMC 4168381. PMID 24446723.
  2. Bonkowski MS, Sinclair DA (November 2016). "+ and sirtuin-activating compounds". Nature Reviews. Molecular Cell Biology. 17 (11): 679–690. doi:10.1038/nrm.2016.93. PMC 5107309. PMID 27552971.
  3. Miyaji N, Nishida K, Tanaka T, Araki D, Kanzaki N, Hoshino Y, et al. (January 2020). "Inhibition of Knee Osteoarthritis Progression in Mice by Administering SRT2014, an Activator of Silent Information Regulator 2 Ortholog 1". Cartilage. 13 (2_suppl): 1356S–1366S. doi:10.1177/1947603519900795. PMC 8804762. PMID 31989845.
  4. Gu C, Zhang Q, Ni D, Xiao QF, Cao LF, Fei CY, et al. (August 2020). "Therapeutic Effects of SRT2104 on Lung Injury in Rats with Emphysema via Reduction of Type II Alveolar Epithelial Cell Senescence". Copd. 17 (4): 444–451. doi:10.1080/15412555.2020.1797657. PMID 32722945. S2CID 220852823.

Share this article:

This article uses material from the Wikipedia article SRT2104, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.